home  aisling capital  life sciences private equity toggle navigation developing treatments for food allergies using standardized pharmaceuticalgrade food allergens and characterized oral desensitization immunotherapy learn more about aimmune innovative medicines for the treatment of hormonallydriven cancers aisling congratulates the management teams of aragon and seragon on their recent acquisitions by johnson  johnson and genentech respectively learn morelearn more about aragon  seragon coolsculpting® more science less fat aisling congratulates the management team of zeltiq on its recent acquisition by allergan learn more about zeltiq largest provider of biopharmaceutical development and commercial outsourcing services learn more about quintiles dalvance™ for the treatment of acute bacterial skin and skin structure infections aisling congratulates the management team of durata on its recent acquisition by actavis learn more about durata diagnostics to accurately identify sepsis pathogens in hours instead of days learn more about t biosystems t biosystems aragon  seragon aisling capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products services and technologies meet our team a combined  years of experience in the healthcare industry learn more see our portfolio  billion in assets with a track record of investing and returning capital since  learn more latest news t biosystems receives ce mark for tbacteria™ panel enabling commercialization in europe july   lexington mass july   globe newswire  t biosystems inc nasdaqttoo an emerging leader in the development of innovative diagnostic products to improve patient health announced today that it has received a ce… read more menlo therapeutics raises m july   menlo park calif july   prnewswire  menlo therapeutics inc announced today that the company has raised m to advance development of serlopitant a novel nk receptor antagonist as a oncedaily oral treatment… read more paratek announces phase  study of oralonly dosing of omadacycline met all primary and secondary fda and ema efficacy endpoints in acute bacterial skin infections july   boston july   globe newswire  paratek pharmaceuticals inc nasdaqprtk announced today positive topline results from a pivotal phase  clinical study comparing its oncedaily oral investigational antibiotic omadacycline to twicedaily oral linezolid… read more more news team  aisling capital  life sciences private equity toggle navigation team aisling capital team aisling capital is led by a group of investment professionals with diverse backgrounds in industry science and finance the team’s complementary backgrounds give aisling capital unique perspective on the key players events and forces shaping the life science industry and allow the fund to identify investment opportunities in working with our portfolio companies the principals of aisling capital seek to provide the financing relationships and guidance needed to build highly successful companies steven a elms managing partner steven a elms mr elms joined aisling in july of  and currently serves as one of the managing partners previously he was a principal in the life sciences investment banking group of hq during his five years at hq mr elms was involved in over  financing and ma transactions helping clients raise in excess of  billion in capital prior to hq mr elms traded mortgagebacked securities at donaldson lufkin  jenrette his previous healthcare sector experience includes over two years as a pharmaceutical sales representative for marion laboratories and two years as a consultant for the wilkerson group mr elms currently serves as a director of adma biologics earlens and loxo oncology previously he served as a director of advion biosciences ambit biosciences archimica cooperatief avera pharmaceuticals bioenvision cenerx biopharma cidara therapeutics lensar nextwave pharmaceuticals novazyme pharmaceuticals pernix therapeutics scerene healthcare and tria beauty and was chairman of the board of adams respiratory therapeutics map pharmaceuticals and oculex pharmaceuticals mr elms received his mba from the kellogg graduate school of management at northwestern university and his ba in human biology from stanford university andrew schiff md managing partner andrew schiff md dr schiff joined aisling in september of  and currently serves as one of the managing partners prior to aisling capital dr schiff practiced internal medicine for six years at the new york presbyterian hospital where he maintains his position as a clinical assistant professor of medicine dr schiff currently serves as a director of armgo pharma powervision and zeltiq aesthetics and as a board observer of zavante therapeutics prior board service includes adams respiratory therapeutics agile therapeutics arginox pharmaceuticals barrier therapeutics bioenvision cardiokine cempra pharmaceuticals miramar labs myogen skinmedica sirion therapeutics transenterix and quintiles board observer he is a longtime supporter and board member of the visiting nurse service of new york dr schiff received his md from cornell university medical college his mba from columbia university and his bs with honors in neuroscience from brown university dov a goldstein md managing partner dov a goldstein md dr goldstein joined aisling in  and currently serves as one of the managing partners prior to joining aisling dr goldstein served as executive vice president and chief financial officer of vicuron pharmaceuticals for five years up until its acquisition by pfizer while at vicuron pharmaceuticals he raised over  million in an ipo pipe followon and block trade transactions he led the valuation and finance due diligence for the merger with biosearch italia nuovo mercato biomi the first us and italian publictopublic company merger he also ran the investor relations and press relations efforts for the company prior to vicuron dr goldstein was director of venture analysis at healthcare ventures he also completed an internship in the department of medicine at columbiapresbyterian hospital dr goldstein currently serves as a director of adma biologics cempra pharmaceuticals and esperion therapeutics previously he served as a director of durata therapeutics acquired by actavis loxo oncology also served as chief financial officer and topaz pharmaceuticals acquired by sanofi and on other private company boards dr goldstein received his md from yale school of medicine he received his mba from columbia business school and his bs with honors from stanford university dennis j purcell founder and senior advisor dennis j purcell mr purcell is the original founder of aisling capital llc and currently serves as a senior advisor to aisling previously he served as the senior managing partner prior to aisling capital mr purcell served as managing director of the life sciences investment banking group at chase hq formerly hambrecht  quist “hq” for over five years while at hq he was directly involved with over two hundred completed transactions and supervised over  billion of financing and advisory assignments in the pharmaceutical biotechnology and medical products industries during his tenure bioworld and other industry publications cited hq as the leading underwriter of life sciences securities prior to joining hq mr purcell was a managing director in the healthcare group at painewebber inc mr purcell is a frequent commentator on the industry and has been honored in the “biotech hall of fame” by genetic engineering news named to the biotechnology allstars list by forbes asap honored as one of the top  irishamerican businessmen and cited as one of the top  contributors to the biotechnology industry mr purcell has served as a director of aton pharma bridge pharmaceuticals cengent therapeutics dynova laboratories paratek pharmaceuticals valentis and xanodyne pharmaceuticals he has served as a member of the advisory council at harvard medical school the board of directors of the biotechnology industry association as well as the new york biotechnology association the irvington institute and on the board of lek consulting he currently sits on the board of real endpoints summus global inc life science leader magazine –editorial advisory board ny bio association and is a member of the university of delaware investment visiting committee member mr purcell received his mba from harvard university and his bs in accounting from the university of delaware eric aguiar md partner eric aguiar md dr aguiar joined aisling in  prior to joining aisling dr aguiar was a partner at thomas mcnerney and partners a  million health care focused venture capital and growth equity fund from  dr aguiar was a managing director of healthcare ventures a health care venture capital fund from  he currently sits on the boards of biohaven and invitae corporation his prior board seats have included amarin oriel therapeutics inc acquired by novartis ag virdante pharmaceuticals inc acquired by momenta pharmaceuticals cardiokine inc acquired by cornerstone therapeutics skinmedica inc acquired by allergan vaxinate inc metaphore and d pharmaceuticals acquired by johnson  johnson he was ceo of genovo inc acquired by targeted genetics a biopharmaceutical company that specialized in gene delivery and gene regulation he was also executive director of theratech inc acquired by watson pharmaceuticals he was a vice president and managing director of philadelphia ventures from  to  dr aguiar is a member of the board of overseers of the tufts school of medicine and a member of the council on foreign relations he received his medical degree with honors from harvard medical school he graduated with honors from cornell university as a college scholar he was also a luce fellow and is a chartered financial analyst aftab r kherani md partner aftab r kherani md dr kherani joined aisling in  and currently serves as a partner previously dr kherani was an engagement manager for two years at mckinsey  company where he was a member of the pharmaceutical medical product and private equity practices prior to mckinsey dr kherani was a chief resident in surgery at duke university medical center where he completed his residency in general surgery he also completed a twoyear postdoctoral research fellowship investigating treatments for heart failure and arrhythmia at columbia university college of physicians  surgeons while at columbia he additionally served as an organ procurement fellow as part of the cardiothoracic transplantation team of new york presbyterian hospital dr kherani currently serves as a director of spirox and transenterix and as a board observer at armgo pharma earlens loxo oncology syros pharmaceuticals and t biosystems dr kherani received his md from duke university school of medicine where he was a howard hughes medical institute research fellowship recipient he also received his bs in biology and ab in economics from duke both magna cum laude graduating phi beta kappa stacey d seltzer partner stacey d seltzer ms seltzer joined aisling in  and currently serves as a partner previously ms seltzer was at scheringplough where she held roles in business development marketing and sales most recently serving as the us scheringplough brand lead for zetia while in business development ms seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions ranging from inlicensing deals to broad development and commercialization alliances prior to scheringplough ms seltzer was the director of business development for akceli a biotechnology company developing cellbased microarrays ms seltzer began her career as a management consultant for mckinsey  company ms seltzer serves as a director of aimmune therapeutics miramar labs and promentis pharmaceuticals and as a board observer of prolacta bioscience previously she served as a board observer for agile therapeutics durata therapeutics acquired by actavis and zeltiq aesthetics she also acted as the aisling representative for its investment in precision dermatology acquired by valeant and was closely involved in aisling’s investments in cytos dermira and powervision ms seltzer received her mba from the wharton school at the university of pennsylvania where she was a palmer scholar she received her ms and bs from yale university awarded cum laude in molecular biophysics and biochemistry josh bilenker md operating partner josh bilenker md dr bilenker joined aisling in  and currently serves as an operating partner he is president and chief executive officer of loxo oncology an aisling capital iii portfolio company prior to aisling dr bilenker served as a medical officer in the office of oncology drug products at the us food and drug administration for two years while at the fda he conducted clinical reviews of indstage and licensed biologic oncology products prior to joining the fda dr bilenker trained at the university of pennsylvania in internal medicine and medical oncology earning board certification in these specialties dr bilenker currently serves as a director of loxo oncology and viewray previously he served as a director of lensar roka bioscience and t biosystems and as a board observer at aragon pharmaceuticals he is also a board member of the nccn foundation and of bioenterprise dr bilenker received his md from the johns hopkins school of medicine he received his ab from princeton awarded summa cum laude in english scott braunstein md operating partner scott braunstein md dr braunstein serves as an operating partner at aisling capital he is senior vice president strategy and corporate development at pacira pharmaceuticals dr braunstein spent  years as a healthcare analyst and portfolio manager at jp morgan asset management where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates he reviewed pharmaceutical company strategies business models and management teams and provided stock recommendations for the jp morgan asset equity group dr braunstein serves as a director of esperion therapeutics stat medical and the cornell alumni association for the college of agriculture and life sciences dr braunstein received his md from the albert einstein college of medicine and completed his residency in internal medicine at cornell universitynew york hospital he received his bs from cornell university ayman sabi operating partner ayman sabi mr sabi is an independent consultant serving as an operating partner at aisling capital he is the founder of sabi medical group bv and a seasoned entrepreneur with almost  years of fiscal strategic and operational leadership mr sabi founded and led sabi ventures and sabi trading and contracting inc which focused on international trade retail and real estate formerly mr sabi was ceo andor director of white house  black market inc acquired by chico’s inc in  roadhouse grill inc ipo  nasdaq new global llc shopping centers sold  and national retail group inc mr sabi has a bs from north carolina state university wonpyo yun analyst wonpyo yun mr yun joined aisling in july  and serves as an analyst previously mr yun was an analyst in the healthcare investment banking group at credit suisse in new york mr yun holds an ab in molecular biology awarded magna cum laude from princeton university where he also received a certificate in finance robert j wenzel chief financial officer robert j wenzel mr wenzel joined aisling in june  and has served as chief financial officer since april  having previously served as controller for nine years for  years prior to joining aisling he was vice president at lazard alternative investments “lazard” where he supervised the financial reporting of several domestic and offshore private equity funds prior to joining lazard mr wenzel began his career at eisner  lubin llp a midsize public accounting firm where he performed audits and prepared tax reports for a diverse clientele attaining the role of senior accountant mr wenzel received his bba in accounting from baruch college in  and holds his certified public accountant license in the state of new york he is also a member of the american institute of certified public accountants and the new york state society of certified public accountants hannah wieder controller hannah wieder ms wieder joined aisling in march  and serves as the controller prior to joining aisling she was an audit manager in the wealth  asset management practice at ernst  young where her focus was on private equity ms wieder also spent six years in the financial services group at cohnreznick a midsize public accounting firm where she attained the role of audit manager and directed the annual audits of various clients within the financial services industry including private equity funds funds of funds and management companies ms wieder received her ms in accountancy from the zicklin school of business at baruch college and received her bs in business management and finance awarded magna cum laude from brooklyn college she is a certified public accountant licensed in the state of new york and is a member of the american institute of certified public accountants and the new york state society of certified public accountants jan hoerrner director of investor relations and marketing jan hoerrner ms hoerrner joined aisling in october of  and serves as the director of investor relations and marketing at aisling capital in this role ms hoerrner manages relationships with over eighty limited partners and is a key contributor in aisling’s fundraising and marketing efforts previously ms hoerrner was with hq a leading underwriter and strategic advisor to the biotechnology industry during her five years at hq ms hoerrner was responsible for coordinating their healthcare conferences and also served as administrative manager for the new york office ms hoerrner received her bs in business administration from bryant university about  aisling capital  life sciences private equity toggle navigation about a differentiated approach to healthcare aisling capital is a leading investment firm that invests in products technologies and global businesses that advance health since  aisling capital has raised over  billion in committed capital across four funds aisling capital invests in both private and public companies utilizing a wide variety of investment structures the aisling capital team’s combination of clinical operational and financial experience allows the firm to identify execute and realize investments across the life sciences industry investment professionals with a combined  years of experience in the healthcare industry billion dollars raised in committed capital across  funds with a track record of investing and returning capital since  investments made to date across development stage and capital structure including both private and public companies our strategy aisling capital seeks to identify differentiated healthcare products services and technologies that address unmet medical needs our business is to provide promising companies with meaningful capital resources and to assist them in achieving their growth objectives we identify healthcare companies at a stage in their development where an infusion of capital and strategic assistance will significantly enhance the opportunities for success our investments aisling capital makes investment decisions driven by fundamental assessment of scientific regulatory financial and commercial risks given our investment team’s broad skillset we invest across the life sciences including seed and venture financings of developmentstage companies smallcap publicly traded equities structured debt and royalty deals and largecap leveraged buyouts of profitable companies our approach aisling capital takes an active approach to investing working closely with portfolio companies to help them become valuebuilding enterprises with multiple opportunities for exit our investment professionals collaborate with management teams and contribute expertise and experience to help determine and execute strategy identify and evaluate business opportunities and address financial issues jan hoerrner  aisling capital toggle navigation team aisling capital team aisling capital is led by a group of investment professionals with diverse backgrounds in industry science and finance the team’s complementary backgrounds give aisling capital unique perspective on the key players events and forces shaping the life science industry and allow the fund to identify investment opportunities in working with our portfolio companies the principals of aisling capital seek to provide the financing relationships and guidance needed to build highly successful companies steven a elms managing partner steven a elms mr elms joined aisling in july of  and currently serves as one of the managing partners previously he was a principal in the life sciences investment banking group of hq during his five years at hq mr elms was involved in over  financing and ma transactions helping clients raise in excess of  billion in capital prior to hq mr elms traded mortgagebacked securities at donaldson lufkin  jenrette his previous healthcare sector experience includes over two years as a pharmaceutical sales representative for marion laboratories and two years as a consultant for the wilkerson group mr elms currently serves as a director of adma biologics earlens and loxo oncology previously he served as a director of advion biosciences ambit biosciences archimica cooperatief avera pharmaceuticals bioenvision cenerx biopharma cidara therapeutics lensar nextwave pharmaceuticals novazyme pharmaceuticals pernix therapeutics scerene healthcare and tria beauty and was chairman of the board of adams respiratory therapeutics map pharmaceuticals and oculex pharmaceuticals mr elms received his mba from the kellogg graduate school of management at northwestern university and his ba in human biology from stanford university andrew schiff md managing partner andrew schiff md dr schiff joined aisling in september of  and currently serves as one of the managing partners prior to aisling capital dr schiff practiced internal medicine for six years at the new york presbyterian hospital where he maintains his position as a clinical assistant professor of medicine dr schiff currently serves as a director of armgo pharma powervision and zeltiq aesthetics and as a board observer of zavante therapeutics prior board service includes adams respiratory therapeutics agile therapeutics arginox pharmaceuticals barrier therapeutics bioenvision cardiokine cempra pharmaceuticals miramar labs myogen skinmedica sirion therapeutics transenterix and quintiles board observer he is a longtime supporter and board member of the visiting nurse service of new york dr schiff received his md from cornell university medical college his mba from columbia university and his bs with honors in neuroscience from brown university dov a goldstein md managing partner dov a goldstein md dr goldstein joined aisling in  and currently serves as one of the managing partners prior to joining aisling dr goldstein served as executive vice president and chief financial officer of vicuron pharmaceuticals for five years up until its acquisition by pfizer while at vicuron pharmaceuticals he raised over  million in an ipo pipe followon and block trade transactions he led the valuation and finance due diligence for the merger with biosearch italia nuovo mercato biomi the first us and italian publictopublic company merger he also ran the investor relations and press relations efforts for the company prior to vicuron dr goldstein was director of venture analysis at healthcare ventures he also completed an internship in the department of medicine at columbiapresbyterian hospital dr goldstein currently serves as a director of adma biologics cempra pharmaceuticals and esperion therapeutics previously he served as a director of durata therapeutics acquired by actavis loxo oncology also served as chief financial officer and topaz pharmaceuticals acquired by sanofi and on other private company boards dr goldstein received his md from yale school of medicine he received his mba from columbia business school and his bs with honors from stanford university dennis j purcell founder and senior advisor dennis j purcell mr purcell is the original founder of aisling capital llc and currently serves as a senior advisor to aisling previously he served as the senior managing partner prior to aisling capital mr purcell served as managing director of the life sciences investment banking group at chase hq formerly hambrecht  quist “hq” for over five years while at hq he was directly involved with over two hundred completed transactions and supervised over  billion of financing and advisory assignments in the pharmaceutical biotechnology and medical products industries during his tenure bioworld and other industry publications cited hq as the leading underwriter of life sciences securities prior to joining hq mr purcell was a managing director in the healthcare group at painewebber inc mr purcell is a frequent commentator on the industry and has been honored in the “biotech hall of fame” by genetic engineering news named to the biotechnology allstars list by forbes asap honored as one of the top  irishamerican businessmen and cited as one of the top  contributors to the biotechnology industry mr purcell has served as a director of aton pharma bridge pharmaceuticals cengent therapeutics dynova laboratories paratek pharmaceuticals valentis and xanodyne pharmaceuticals he has served as a member of the advisory council at harvard medical school the board of directors of the biotechnology industry association as well as the new york biotechnology association the irvington institute and on the board of lek consulting he currently sits on the board of real endpoints summus global inc life science leader magazine –editorial advisory board ny bio association and is a member of the university of delaware investment visiting committee member mr purcell received his mba from harvard university and his bs in accounting from the university of delaware eric aguiar md partner eric aguiar md dr aguiar joined aisling in  prior to joining aisling dr aguiar was a partner at thomas mcnerney and partners a  million health care focused venture capital and growth equity fund from  dr aguiar was a managing director of healthcare ventures a health care venture capital fund from  he currently sits on the boards of biohaven and invitae corporation his prior board seats have included amarin oriel therapeutics inc acquired by novartis ag virdante pharmaceuticals inc acquired by momenta pharmaceuticals cardiokine inc acquired by cornerstone therapeutics skinmedica inc acquired by allergan vaxinate inc metaphore and d pharmaceuticals acquired by johnson  johnson he was ceo of genovo inc acquired by targeted genetics a biopharmaceutical company that specialized in gene delivery and gene regulation he was also executive director of theratech inc acquired by watson pharmaceuticals he was a vice president and managing director of philadelphia ventures from  to  dr aguiar is a member of the board of overseers of the tufts school of medicine and a member of the council on foreign relations he received his medical degree with honors from harvard medical school he graduated with honors from cornell university as a college scholar he was also a luce fellow and is a chartered financial analyst aftab r kherani md partner aftab r kherani md dr kherani joined aisling in  and currently serves as a partner previously dr kherani was an engagement manager for two years at mckinsey  company where he was a member of the pharmaceutical medical product and private equity practices prior to mckinsey dr kherani was a chief resident in surgery at duke university medical center where he completed his residency in general surgery he also completed a twoyear postdoctoral research fellowship investigating treatments for heart failure and arrhythmia at columbia university college of physicians  surgeons while at columbia he additionally served as an organ procurement fellow as part of the cardiothoracic transplantation team of new york presbyterian hospital dr kherani currently serves as a director of spirox and transenterix and as a board observer at armgo pharma earlens loxo oncology syros pharmaceuticals and t biosystems dr kherani received his md from duke university school of medicine where he was a howard hughes medical institute research fellowship recipient he also received his bs in biology and ab in economics from duke both magna cum laude graduating phi beta kappa stacey d seltzer partner stacey d seltzer ms seltzer joined aisling in  and currently serves as a partner previously ms seltzer was at scheringplough where she held roles in business development marketing and sales most recently serving as the us scheringplough brand lead for zetia while in business development ms seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions ranging from inlicensing deals to broad development and commercialization alliances prior to scheringplough ms seltzer was the director of business development for akceli a biotechnology company developing cellbased microarrays ms seltzer began her career as a management consultant for mckinsey  company ms seltzer serves as a director of aimmune therapeutics miramar labs and promentis pharmaceuticals and as a board observer of prolacta bioscience previously she served as a board observer for agile therapeutics durata therapeutics acquired by actavis and zeltiq aesthetics she also acted as the aisling representative for its investment in precision dermatology acquired by valeant and was closely involved in aisling’s investments in cytos dermira and powervision ms seltzer received her mba from the wharton school at the university of pennsylvania where she was a palmer scholar she received her ms and bs from yale university awarded cum laude in molecular biophysics and biochemistry josh bilenker md operating partner josh bilenker md dr bilenker joined aisling in  and currently serves as an operating partner he is president and chief executive officer of loxo oncology an aisling capital iii portfolio company prior to aisling dr bilenker served as a medical officer in the office of oncology drug products at the us food and drug administration for two years while at the fda he conducted clinical reviews of indstage and licensed biologic oncology products prior to joining the fda dr bilenker trained at the university of pennsylvania in internal medicine and medical oncology earning board certification in these specialties dr bilenker currently serves as a director of loxo oncology and viewray previously he served as a director of lensar roka bioscience and t biosystems and as a board observer at aragon pharmaceuticals he is also a board member of the nccn foundation and of bioenterprise dr bilenker received his md from the johns hopkins school of medicine he received his ab from princeton awarded summa cum laude in english scott braunstein md operating partner scott braunstein md dr braunstein serves as an operating partner at aisling capital he is senior vice president strategy and corporate development at pacira pharmaceuticals dr braunstein spent  years as a healthcare analyst and portfolio manager at jp morgan asset management where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates he reviewed pharmaceutical company strategies business models and management teams and provided stock recommendations for the jp morgan asset equity group dr braunstein serves as a director of esperion therapeutics stat medical and the cornell alumni association for the college of agriculture and life sciences dr braunstein received his md from the albert einstein college of medicine and completed his residency in internal medicine at cornell universitynew york hospital he received his bs from cornell university ayman sabi operating partner ayman sabi mr sabi is an independent consultant serving as an operating partner at aisling capital he is the founder of sabi medical group bv and a seasoned entrepreneur with almost  years of fiscal strategic and operational leadership mr sabi founded and led sabi ventures and sabi trading and contracting inc which focused on international trade retail and real estate formerly mr sabi was ceo andor director of white house  black market inc acquired by chico’s inc in  roadhouse grill inc ipo  nasdaq new global llc shopping centers sold  and national retail group inc mr sabi has a bs from north carolina state university wonpyo yun analyst wonpyo yun mr yun joined aisling in july  and serves as an analyst previously mr yun was an analyst in the healthcare investment banking group at credit suisse in new york mr yun holds an ab in molecular biology awarded magna cum laude from princeton university where he also received a certificate in finance robert j wenzel chief financial officer robert j wenzel mr wenzel joined aisling in june  and has served as chief financial officer since april  having previously served as controller for nine years for  years prior to joining aisling he was vice president at lazard alternative investments “lazard” where he supervised the financial reporting of several domestic and offshore private equity funds prior to joining lazard mr wenzel began his career at eisner  lubin llp a midsize public accounting firm where he performed audits and prepared tax reports for a diverse clientele attaining the role of senior accountant mr wenzel received his bba in accounting from baruch college in  and holds his certified public accountant license in the state of new york he is also a member of the american institute of certified public accountants and the new york state society of certified public accountants hannah wieder controller hannah wieder ms wieder joined aisling in march  and serves as the controller prior to joining aisling she was an audit manager in the wealth  asset management practice at ernst  young where her focus was on private equity ms wieder also spent six years in the financial services group at cohnreznick a midsize public accounting firm where she attained the role of audit manager and directed the annual audits of various clients within the financial services industry including private equity funds funds of funds and management companies ms wieder received her ms in accountancy from the zicklin school of business at baruch college and received her bs in business management and finance awarded magna cum laude from brooklyn college she is a certified public accountant licensed in the state of new york and is a member of the american institute of certified public accountants and the new york state society of certified public accountants jan hoerrner director of investor relations and marketing jan hoerrner ms hoerrner joined aisling in october of  and serves as the director of investor relations and marketing at aisling capital in this role ms hoerrner manages relationships with over eighty limited partners and is a key contributor in aisling’s fundraising and marketing efforts previously ms hoerrner was with hq a leading underwriter and strategic advisor to the biotechnology industry during her five years at hq ms hoerrner was responsible for coordinating their healthcare conferences and also served as administrative manager for the new york office ms hoerrner received her bs in business administration from bryant university aisling capital llc private company information  bloomberg july    pm et capital markets company overview of aisling capital llc snapshot people company overview aisling capital llc is a venture capital and private equity firm specializing in investments in seed and venture financings of developmentstage mid venture growth capital industry consolidations product acquisitions positioning companies in the public stock markets and followon financings the firm focuses on smallcap publicly traded equities structured debt and royalty deals and largecap leveraged buyouts the firm seeks to invest in life sciences healthcare products services and technologies it typically invests in private and public healthcare companies life science companies developing pharmaceutical biotechnology medical products alternative energy resources and bus aisling capital llc is a venture capital and private equity firm specializing in investments in seed and venture financings of developmentstage mid venture growth capital industry consolidations product acquisitions positioning companies in the public stock markets and followon financings the firm focuses on smallcap publicly traded equities structured debt and royalty deals and largecap leveraged buyouts the firm seeks to invest in life sciences healthcare products services and technologies it typically invests in private and public healthcare companies life science companies developing pharmaceutical biotechnology medical products alternative energy resources and businesses that advance health and provide drug development manufacturing and other important services to the healthcare industry the firm typically invests between  million and  million or more in new capital it usually participates in further rounds of financing following the initial investment the firm prefers to be a lead or colead investor in its transactions it seeks a board seat in its portfolio companies aisling capital llc was founded in  and is based at new york new york detailed description  seventh avenueth floornew york ny united statesfounded in  phone  fax  wwwaislingcapitalcom key executives for aisling capital llc mr dennis j purcell mba founder and senior advisor age  mr robert j wenzel cpa chief financial officer mr steven a elms managing partner age  dr andrew n schiff md managing partner and managing director age  dr dov a goldstein md mba managing partner age  compensation as of fiscal year  aisling capital llc key developments aisling capital llc presents at the  biotech ceo summit europe ireland jul  pm jul   aisling capital llc presents at the  biotech ceo summit europe ireland jul  pm venue powerscourt hotel enniskerry county wicklow ireland speakers dennis j purcell founder and senior advisor aisling capital llc presents at superreturn us east jun through jun jun   aisling capital llc presents at superreturn us east jun through jun venue renaissance boston waterfront hotel boston united states presentation date  speakers jun stacey d seltzer partner jun andrew n schiff managing partner and managing director aisling capital llc presents at th annual bio ceo  investor conference feb  pm jan   aisling capital llc presents at th annual bio ceo  investor conference feb  pm venue the waldorf astoria new york  park avenue new york ny  united states speakers dennis j purcell founder and senior advisor similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target private placement july   menlo therapeutics inc mergeracquisition july   spirox inc mergeracquisition june   miramar labs inc request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact aisling capital llc please visit wwwaislingcapitalcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close about  aisling capital  life sciences private equity toggle navigation about a differentiated approach to healthcare aisling capital is a leading investment firm that invests in products technologies and global businesses that advance health since  aisling capital has raised over  billion in committed capital across four funds aisling capital invests in both private and public companies utilizing a wide variety of investment structures the aisling capital team’s combination of clinical operational and financial experience allows the firm to identify execute and realize investments across the life sciences industry investment professionals with a combined  years of experience in the healthcare industry billion dollars raised in committed capital across  funds with a track record of investing and returning capital since  investments made to date across development stage and capital structure including both private and public companies our strategy aisling capital seeks to identify differentiated healthcare products services and technologies that address unmet medical needs our business is to provide promising companies with meaningful capital resources and to assist them in achieving their growth objectives we identify healthcare companies at a stage in their development where an infusion of capital and strategic assistance will significantly enhance the opportunities for success our investments aisling capital makes investment decisions driven by fundamental assessment of scientific regulatory financial and commercial risks given our investment team’s broad skillset we invest across the life sciences including seed and venture financings of developmentstage companies smallcap publicly traded equities structured debt and royalty deals and largecap leveraged buyouts of profitable companies our approach aisling capital takes an active approach to investing working closely with portfolio companies to help them become valuebuilding enterprises with multiple opportunities for exit our investment professionals collaborate with management teams and contribute expertise and experience to help determine and execute strategy identify and evaluate business opportunities and address financial issues aisling capital llc company profile  bloomberg feedback aisling capital llc private company company profile sector financials industry asset management subindustry private equity aisling capital llc operates as a venture capital firm the company invests in products technologies and global businesses that advance health aisling capital serves customers in the state of new york corporate information address  seventh avenue th floor new york ny  united states phone  fax  web url wwwaislingcapitalcom from the web key executives steve elms managing partner andrew n schiff drew managing partner dov a goldstein managing partner eric aguiar partner aftab r kherani partner stacey d seltzer partner joshua h bilenker josh operating partner scott braunstein operating partner ayman sabi operating partner robert j wenzel chief financial officer jan hoerrner dirinvestor relations  mktg hannah wieder controller show more show less sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data aisling capital llc  law search advanced search take a free trial  sign in close law indepth law uk adv search  platform tools browse all sections banking bankruptcy class action competition employment energy expert analysis insurance intellectual property product liability securities rankings laws mvps glass ceiling report global  law  diversity snapshot practice group partner rankings practice groups of the year pro bono firms of the year rising stars trial aces site menu join the law team search legal jobs learn more about law read testimonials contact law sign up for our newsletters site map help aisling capital llc news  case alert on aisling capital llc financial » asset management » aisling capital llc menu options for aisling capital llc everything » news  analysis » new cases » new ptab cases » case activity » outside counsel » data on cases clients outside counsel and individual attorneys collected from active federal civil cases reflects only recently published court data not intended to be exhaustive not responsible for errors in court dockets × please assign a name to this alert save alert cancel news  january   sec fines pershing square others for paytoplay violations  they were adams capital management aisling capital alta communications commonwealth venture january   fenwick guides cancer biotech loxos m followon  loxos largest shareholder is an affiliate of aisling capital an investment firm focused on the life july    ipos targeting b ready to rock st week of august  including longitude venture partners ii lp aisling capital iii lp and foresite capital fund ii lp an cases  no results ptab cases  no results to view all the results and drill down deeper take a free trial now try law free for seven days already a subscriber click here to login × already have access click here to login get instant access to the onestop news source for business lawyers register now get instant access to the onestop news source for business lawyers email professional email required first name last name please note a verification email will be sent to your address before you can access your trial password at least  characters required confirm password select at least one primary interest aerospace  defense appellate asset management automotive banking bankruptcy california capital markets class action commercial contracts competition consumer protection corporate cybersecurity  privacy delaware employment energy environmental financial services uk florida food  beverage government contracts health hospitality illinois immigration insurance insurance uk intellectual property international arbitration international trade law in depth legal ethics life sciences media  entertainment medical malpractice mergers  acquisitions native american new jersey new york pennsylvania private equity product liability project finance public policy real estate retail  e commerce securities sports tax technology telecommunications texas transportation trials white collar register already have access email password forgot your password remember login sign in aisling capital llc  new york ny  company information products resources my account talk to a db advisor  business directory ny new york investors nec investors nec aisling capital llc a aisling capital llc claim this business  th ave fl  new york ny  get directions wwwaislingcapitalcom business info founded  incorporated annual revenue  employee count  industries investors nec contacts  contact business your email address subject message send message verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   a view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocalcom mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call  to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved aisling trademark of aisling capital llc serial number   trademarkia trademarks apply online attorneys services us trademark registration service international trademark registration service trademark office action response trademark statement of use trademark renewal trademark assignment trademark watch trademark cease  desist trademark comprehensive search copyright registration patent services incorporation services business page creation more services help contact us login trademark search trademark category insurance  financial services aisling   get free email alerts aisling trademark information aisling capital llc financial services namely investment management services  investment brokerage services  and investment of funds for others investment advisory and related financial reporting services private equity funding services venture capital services namely providing financing to emerging and startup companies perfect for these industries insurance  financial services words that describe this mark financial   services       investment   management   services       investment   brokerage   services       investment   funds   investment   advisory   related   financial   reporting   services   private   equity   funding   services   this is a brand page for the aisling trademark by aisling capital llc  in new york ny  write a review about a product or service associated with this aisling trademark or contact the owner aisling capital llc of the aisling trademark by filing a request to communicate with the legal correspondent for licensing use andor questions related to the aisling trademark on friday june   a us federal trademark registration was filed for aisling by aisling capital llc new york ny  the uspto has given the aisling trademark serial number of  the current federal status of this trademark filing is registered and renewed the correspondent listed for aisling is claudine meredithgoujon of claudine meredithgoujon  avenue of the americas paul weiss rifkind wharton  garrison new york ny   the aisling trademark is filed in the category of insurance  financial services  the description provided to the uspto for aisling is financial services namely investment management services  investment brokerage services  and investment of funds for others investment advisory and related financial reporting services private equity funding services venture capital services namely providing financing to emerging and startup companies word mark aisling statusstatus date registered and renewed  serial number  filing date  registration number  registration date  goods and services financial services namely investment management services  investment brokerage services  and investment of funds for others investment advisory and related financial reporting services private equity funding services venture capital services namely providing financing to emerging and startup companies mark description not available type of mark service mark published for opposition date  last applicantowner aisling capital llcnew york ny  why is this contact information displayed why is this contact information displayed close the uspto makes this data available for search by the public so that individuals can locate ownership information for intellectual property much the same way a county might make real estate property ownership information available since our website is synchronized with the uspto data we recommend making any data changes with the uspto directly our website will autoupdate when the uspto data is updated you may also contact trademarkia to make a request for the removal of your personally identifiable information or trademark data such requests must be made in writing and will be subject to verification of ownership this policy allows verified trademark owners to specify a that their identifiable information be masked or b that their trademark pages permanently deleted from trademarkiacom requests may be made directly to customerservicetrademarkiacom and every effort will be made to honor them within  hours click here for further details close mark drawing code standard character mark design search no data register type principal disclaimer not available correspondent claudine meredithgoujon claudine meredithgoujon  avenue of the americas paul weiss rifkind wharton  garrison new york ny  use in commerce trademark  applicant has provided proof of use of this mark in commerce to uspto classification information primary class class   insurance financial affairs monetary affairs real estate affairs first use anywhere  first use in commerce  trademarkia is the largest search engine for us trademarks each month hundreds of trademarks around the world are filed by licensed attorneys in the legalforcetrademarkia network you can register your trademark in  countries in the world through legalforce network legalforce network can help you incorporate a business around your aisling trademark in less than  minutes trademarkia makes the process easy and convenient so start now trademarkiacom is a free search engine of publicly available government records trademarkiacom is not a law firm and does not represent owners  correspondents listed on this page trademark document retrieval  trademark  apply online  satisfaction guarantee protect your valuable brand now how it works what you get  legalforce rapc   us trademark filing from  to now  describe how your business or product is being used register your mark in  countries just   govt fees start here   top global ip attorneys  credibility and experience  all processes will be performed in a timely manner you will be informed periodically about the process keep track of this brand trademark watch services keep track of how your trademark is being used available in the united states and in more than  countries roundtheclock monitoring monthly report on potential infringement watch this trademark trademark watch services read more current trademark status  registered and renewed free trademark search correspondent search claudine meredithgoujon is a correspondent of aisling trademark current overall rating  review what you can do start your business free logo creator add to favorites view documents free trademark search start trademark filing process protect this mark internationally custom logo design  search aisling on popular social networks trademarkia lets you see how your personal name product name trademark name or username is being used on any of  new and popular social networks be the first to reserve your name and get help stopping others from using it  all in one place trademark oppose service you can request for extension of time to oppose this mark or oppose it now  if you are new to legalforcetrademarkia please just enter your contact email and create a password  if you already have a legalforcetrademarkia account please enter your accounts email and password  email address please enter your email address  enter password please enter your password  please enter the value       status update alerts status update alerts are email updates of the latest trademark status change please make sure you provide the correct email  if you are new to legalforcetrademarkia please just enter your contact email and create a password  if you already have a legalforcetrademarkia account please enter your accounts email and password  email address please enter your email address  enter password please enter your password  please enter the value       review  rating please rate and review for aisling aisling is providing financial services namely investment management services  investment brokerage services  and investment of funds for others investment advisory and related financial reporting services private equity funding services venture capital services namely providing financing to emerging and startup companies  if you are new to legalforcetrademarkia please just enter your contact email and create a password to be associated with your review if you already have a legalforcetrademarkia account please enter your accounts email and password before posting your review  please rate        your review please enter your review  email address please enter your email address  enter password please enter your password       bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version home  aisling capital  life sciences private equity toggle navigation developing treatments for food allergies using standardized pharmaceuticalgrade food allergens and characterized oral desensitization immunotherapy learn more about aimmune innovative medicines for the treatment of hormonallydriven cancers aisling congratulates the management teams of aragon and seragon on their recent acquisitions by johnson  johnson and genentech respectively learn morelearn more about aragon  seragon coolsculpting® more science less fat aisling congratulates the management team of zeltiq on its recent acquisition by allergan learn more about zeltiq largest provider of biopharmaceutical development and commercial outsourcing services learn more about quintiles dalvance™ for the treatment of acute bacterial skin and skin structure infections aisling congratulates the management team of durata on its recent acquisition by actavis learn more about durata diagnostics to accurately identify sepsis pathogens in hours instead of days learn more about t biosystems t biosystems aragon  seragon aisling capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products services and technologies meet our team a combined  years of experience in the healthcare industry learn more see our portfolio  billion in assets with a track record of investing and returning capital since  learn more latest news t biosystems receives ce mark for tbacteria™ panel enabling commercialization in europe july   lexington mass july   globe newswire  t biosystems inc nasdaqttoo an emerging leader in the development of innovative diagnostic products to improve patient health announced today that it has received a ce… read more menlo therapeutics raises m july   menlo park calif july   prnewswire  menlo therapeutics inc announced today that the company has raised m to advance development of serlopitant a novel nk receptor antagonist as a oncedaily oral treatment… read more paratek announces phase  study of oralonly dosing of omadacycline met all primary and secondary fda and ema efficacy endpoints in acute bacterial skin infections july   boston july   globe newswire  paratek pharmaceuticals inc nasdaqprtk announced today positive topline results from a pivotal phase  clinical study comparing its oncedaily oral investigational antibiotic omadacycline to twicedaily oral linezolid… read more more news bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one